Prevalence
Study
|
N |
Rx |
Prevalence |
Vrouenraets
et al.
|
211 |
No
Rx
|
No
treatment – 4/50 (8%) 2-5 mmol/L
|
|
|
NRTI |
NRTI
treatment – 35/161 (22%) 2-5 mmol/L
|
Harris
et al.
|
331 |
NRTI |
68/331
(21%) >2.1 mmol/L
|
|
|
PI |
27/331
(8%) > 3.0 mmol/L
|
John
et al.
|
349 |
NRTI
|
224/349
(64%) >1.5 mmol/L
|
|
|
PI |
63/349
(18%) >2.5 mmol/L
|
|
|
|
20/349
(6%) 3.5-5 mmol/L
|
|
|
|
5/349
(1%) >5 mmol/L
|
Boubaker
et al.
|
988 |
NRTI |
107/988
(11%) >2 mmol/L
|
|
|
PI |
14/988
(1%) >4 mmol/L
|
•
Various studies have examined the prevalence of hyperlactatemia
in patients being treated with antiretroviral therapy.
• Here is a series of four cohorts. According to these studies,
there seems to be a higher prevalence of increased lactate levels
in patients on antiretroviral therapy consisting of combination
NRTI and protease inhibitors.1
• Depending on the level of abnormality, lactate levels range
anywhere from more than 2 mmol/L to more than 5 mmol/L.
• At the lower levels of lactate, there is a higher prevalence
rate, while the reverse is true for higher lactate levels. Overall,
there is about a 20% prevalence rate of hyperlactatemia associated
with antiretroviral therapy. It is important to remember that these
are asymptomatic patients.
Reference:
1. White et al. Second Adverse Events and Lipodystrophy Workshop,
Toronto, Canada; 2000. Poster 82.
|
|
